Compare ALTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | CLLS |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.0M | 374.2M |
| IPO Year | 2021 | 2014 |
| Metric | ALTI | CLLS |
|---|---|---|
| Price | $4.15 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 97.7K | 32.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $206,935,000.00 | N/A |
| Revenue This Year | $19.78 | $40.37 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $1.10 |
| 52 Week High | $5.45 | $5.48 |
| Indicator | ALTI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 39.15 |
| Support Level | $4.07 | $3.41 |
| Resistance Level | $4.31 | $3.77 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 14.13 | 1.35 |
AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and the International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a track record with risk adjusted return characteristics.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.